FDA schedules advisory committee hearing for Lynparza prostate cancer application
What once appeared to be a slam dunk for Merck and AstraZeneca’s PARP inhibitor Lynparza may no longer be a sure thing.
The FDA will convene an advisory committee to discuss an application to further expand the drug’s label into a broader set of prostate cancer patients, the companies announced Thursday morning. The hearing, run by the Oncologic Drugs Advisory Committee, or ODAC, will take place on April 28.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters